Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4558-4567

  Beer, Tomasz M ^a   Bernstein, Guy T ^b   Corman, John M ^c   Glode, L Michael ^d   Hall, Simon J ^e   Poll, Wayne L ^f   Schellhammer, Paul F ^g   Jones, Lori A ^h   Xu, Yi ^h   Kylstra, Jelle W ⁱ   Frohlich, Mark W ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Center for Urologic Care   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f AKSM Clinical Research Corporation   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h Dendreon   (United States)

ⁱ Spectrum Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PROSTATE SPECIFIC ANTIGEN; PROVENGE; TESTOSTERONE;

ADULT; AGED; ANTIANDROGEN THERAPY; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ARTHRALGIA; ARTICLE; BACKACHE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CHILL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HOT FLUSH; HUMAN; HYPERTENSION; IMMUNE RESPONSE; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYALGIA; NAUSEA; ORAL PARESTHESIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION;

AGED; ANDROGENS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; TREATMENT OUTCOME; UP-REGULATION;

EID: 79960337024     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3223     Document Type: Article

References (38)

1. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate- term results. J Urol 1998;160:2428-34.
2. Eastham JA, Scardino PT. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In:Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Comprehensive textbook of genitourinary oncology. 2nd ed. Philadelphia: Lipincott Williams & Wilkins;1999.
3. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6. (Pubitemid 24322640)
4. Clark PE, Levin HS, Kupelian PA, Reddy C, Zippe CD, Klein EA. Intermediate-term outcome with radical prostatectomy for localized prostate cancer: The Cleveland Clinic experience. The Prostate J 2001;3:118-25. (Pubitemid 34169209)
5. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;CD003506.
6. Walsh PC, De Weese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001;166:508-15;discussion 15-6.
7. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44. (Pubitemid 41043794)
8. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003;44:209-14. (Pubitemid 36917005)
9. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
10. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebocontrolled, phase 3 trials of active cellular immunotherapy with sipuleucel- T in advanced prostate cancer. Cancer 2009;115: 3670-9.
11. Kantoff P, Higano C, Shore N, Berger ER, Small EJ, Penson DF, et al. A randomized, placebo-controlled, phase 3 trial of active cellular immunotherapy with Sipuleucel-T in metastatic castration-resistant prostate cancer. NEJM 2010;363:411-22.
12. Sheikh N A, Jones L A. CD54 is a marker of antigen presenting cell activation. Cancer Immunol Immunother 2008;57:1381-90.
13. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 2007;25:3680-7. (Pubitemid 47372607)
14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 1999;18:695-706. (Pubitemid 29126745)
15. Augustin H, Freibauer C, Bayer L, Lunglmayr G, Tschurlovich F, Kuber W, et al. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression. Prostate Cancer Prostatic Dis 2006;9:279-83. (Pubitemid 44317263)
16. Akyol F, Ozyigit G, Selek U, Karabulut E. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol 2005;48:40-5. (Pubitemid 40835588)
17. Bates AT, Pickles T, Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:148-53. (Pubitemid 40591936)
18. Kobayashi T, Nishizawa K, Mitsumori K. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Scand J Urol Nephrol 2006;40:198-203. (Pubitemid 43785978)
19. Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008;180:1432-7;discussion 7.
20. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology 1993;42:390-7. (Pubitemid 23314330)
21. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004:S42-6;discussion S6-7.
22. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004;171:2221-5. (Pubitemid 38625438)
23. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
24. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000;48:629-33.
25. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007;25:1765-71. (Pubitemid 46797959)
26. Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, et al. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 2006;66:1064-71. (Pubitemid 44633505)
27. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, et al. Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. J Urol 2008;179:2181-2186.
28. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
29. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82. (Pubitemid 30399182)
30. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197-204. (Pubitemid 38971831)
31. Kantoff PW, Schoetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
32. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
33. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
34. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71.
35. Oliver RT, Joseph JV, Gallagher CJ. Castration-induced lymphocytosis in prostate cancer: possible evidence for gonad/thymus endocrine interaction in man. Urol Int 1995;54:226-9.
36. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-53. (Pubitemid 41113891)
37. Mercader M, Bodner BK, Moser MT, Uldrich AP, Berzins SP, Heng TS, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70. (Pubitemid 33121432)
38. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49. (Pubitemid 40568683)